Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 603

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 3
Chunk 603
---
 served as a director of Travere Therapeutics (Nasdaq: TVTX). Mr. Meckler served as Chief Executive
Officer and a director of CoCrystal Pharma, Inc., a pharmaceutical company, from April 2015 to July 2016. He has also served as a director
of QLT, Inc. (Nasdaq: QLTI), a biotechnology company, from June 2012 to November 2016, as well as the Managing Director of The Andra
Group, a life sciences consulting firm since 2009. Mr. Meckler also served as Chief Executive Officer of Trieber Therapeutics from January
2017 to July 2017. Earlier in his career, Mr. Meckler held a series of positions at Pfizer Inc. in manufacturing systems, market research,
business development, strategic planning and corporate finance, which included playing a significant role in acquisitions and divestitures.
Mr. Meckler is the past President and continues to serve on the board of directors of Children of Bellevue, a non-profit organization
focused on advocating and developing pediatric programs at Bellevue Hospital Center. Mr. Meckler holds a B.S. in Industrial Management
and M.S. in Industrial Administration from Carnegie Mellon University. In addition, Mr. Meckler received his J.D. from Fordham University
School of Law. We believe that Mr. Meckler is qualified to serve on our board of directors because of his extensive executive leadership
experience in the biopharmaceutical industry, including his service at Pfizer, and his experience serving on public company boards.

72

Michael
J. Newman, Ph.D. has served as our Chief Scientific Officer and a member of our board of directors since August 2021. Dr. Newman
is a pharmaceutical/biotechnology executive with over 40 years of experience carrying out and managing oncology research and development,
in addition to undergraduate and graduate research and training in microbiology. He was the Founder, President, Chief Executive Officer
and a member of the board of directors of Decoy (from August 2013 to August 2021). His previous positions also include faculty appointments
in Biochemistry at Brandeis University (from 1984 to 1987) and the Roche Institute of Molecular Biology (from 1987 to 1992), Senior Associate
Director of Oncology at Sandoz Pharmaceuticals (world-wide head of Cancer Biology), and Executive Director of Oncology at Novartis Pharmaceuticals